AI Drug Discovery Company of 2024
Our award winning discoveries are recognized by industry peers as being the future of AI drug discovery.
​
DNA SEQ's discoveries aim to provide life giving solutions to address numerous cancer indications including: lung, breast, bladder, gallbladder, melanoma and leukemia.
​
Discoveries that will reshape the future.
See what they said!
DNA SEQ are the global pioneers of using ML & AI with actual results
We have already achieved what others claim they might do in the future. We have data to demonstrate that we lead the field with
-
303 novel DFG INTER kinase drug candidates
-
targeting 6 cancer indications
-
Proof-of-concept for drug resistant patients with leukemia
DNA SEQ has awarded patents over the methods of core discoveries to reshape the pharmaceutical industry.
​
DFG INTER binding sites incorporate the substrate and have allosteric binding site features.
Repeating the impossible
Janusz Sowadski, our CSO, was a director of the team who discovered the first 3D structure of a kinase which led to the FDA approved drug Gleevec ® and the creation of the kinase inhibitor market. Our goal is to build on that experience with our DFG INTER concept using many of the same experts. These people include Dr Janusz Sowadski, Dr Brian Druker (Knight Cancer Institute), Dr Tony Hunter (SALK Institute) and Dr Walter Gilbert (Nobel Laureate) among many other dedicated and incredible people who support DNA SEQ's scientific discoveries.
Conversations with Global Experts
Hear from globally recognized kinase expert Dr. Tony Hunter of the Salk Institute about DNA SEQ's discoveries.
What have we discovered?
Nearly all FDA approved drugs bind to these two sites
DFG IN
DFG OUT
DFG INTER - a revolutionary discovery
DNA SEQ discovered a new drug structure to address mutant resistance and downstream signaling in order to overcome cancers resistance to existing targeted drug therapies - the next revolution in cancer treatment.
Read the letter of support provided to us by Dr. Brian Druker from the Knight Cancer Institute supporting the discoveries of DNA SEQ.
Mutational resistance
Kinases are proteins in our bodies that have many important roles, including helping to control the growth of cells. Sometimes, these kinases can malfunction, leading to diseases like cancer.
​
Some drugs are designed to target and inhibit (slow down or stop) these malfunctioning kinases, helping to control the disease. However, over time, the genes that produce these kinases can mutate, or change. These changes can cause the kinase's structure to change as well.
​
If the structure of the kinase changes, the drug might not be able to bind to it or affect it as effectively anymore. It's kind of like trying to fit a key into a lock that's changed its shape - the key can't work if it doesn't match the lock.
​
So, when a kinase changes due to mutation, it can become resistant to the drug that was designed to target it. This is known as mutational drug resistance. This is a significant challenge in the treatment of diseases like cancer, because it can make drugs less effective over time.
​
DNA SEQ understands how to build drugs to address the resistance due to mutations at a binding site referred to as DFG INTER. We have patented the methods of discovery.
Targeting the substrate site
Why is solving the issue of downstream signaling crucial?
-
Targeted Therapy: If we can understand and control downstream signaling, we could potentially stop or slow the progress of many types of cancer at a molecular level. Drugs could be developed to target specific points in the signaling pathway, essentially "turning off" the malfunctioning kinase or correcting the signal downstream, halting the uncontrolled growth of cells.
-
Personalized Medicine: Each patient's cancer may involve different mutations and signaling pathways. Understanding these would allow us to create highly personalized treatments that target the specific oncogenic kinases involved in each patient's cancer.
-
Prevention and Early Detection: Understanding these pathways could also lead to better strategies for cancer prevention and early detection. If we can identify key markers of abnormal downstream signaling, we might be able to catch cancer earlier, when it's more treatable.
Even when drugs are bound to a kinase, it can communicate through many other complex mechanisms to create cancer downstream. Targeting the substrate site allows us to create drugs that shut down the downstream signaling associated with cancers resistance to existing targeted therapies.
In essence, solving the issue of oncogenic kinase's downstream signaling can lead to significant strides in cancer treatment, potentially saving millions of lives and transforming the world of medicine.
AI driven platform for new small molecule drug discoveries
Our awarded patent creates a virtual “fishing net” to identify the small molecules which make ideal drug candidates. We have identified molecules that can target 6 cancer indications.
​
We have also developed additional AI capabilities that optimize the molecular docking process for optimizing the medicinal chemistry required for success.
How does our patented technology work in simple terms?
Thousands of molecules tested in our algorithm
High quality drug candidates are identified
Crystallization and chemistry
By creating a 3-D representation of the molecule we are then able to determine the exact chemistry to attach the molecule to new target binding sites. This novel approach allows us to overcome resistance using our AI platform.
We are selecting and designing our molecules based upon patient data who became resistant to cancer therapies, providing us with the exact requirements for effective drug design that we hypothesize will be much less susceptible to the development of drug resistance.